ABBV
AbbVie Inc.
NYSE: ABBV · North Chicago, IL · Healthcare
$259.36+2.44 (+0.95%)Closed
Market Cap$458.24B
Cash$9.39Bmost recent
Runwayprofitable
P/E (TTM)109.9EPS $2.36
52-Wk Range$182.85 – $259.36
Avg Volume6.4M3-month
Price & Trading Activity

Daily close with catalyst overlays and trading volume

$259.36+52.0%
Pipeline

Drug candidates sponsored by AbbVie · ClinicalTrials.gov

77 drugs · 100 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 4Lopinavir/Ritonavir
HIV Infection
Completed
2008-01past
1
Phase 4Risankizumab
Inflammatory Bowel Disease+3 more
Completed
2026-02-05past
5
Phase 4Venetoclax
Acute Myeloid Leukemia (AML)+4 more
Recruiting
2027-11
5
Phase 3ABT-450/r/ABT-267, ABT-333
Chronic Hepatitis C Infection
Completed
2013-12past
2
Phase 3Levodopa-carbidopa intestinal gel
Advanced Parkinson's Disease
Completed
2015-03past
2
Phase 3ombitasvir/paritaprevir/ritonavir
Chronic Hepatitis C+2 more
Completed
2016-06-13past
1
Phase 3ombitasvir/paritaprevir/ritonavir and dasabuvir
Chronic Hepatitis C Infection
Completed
2016-07-04past
1
Phase 3ABT-450/r/ABT-267
Hepatitis C Virus+4 more
Completed
2016-07-21past
2
Phase 2ABT-493, ABT-530
Chronic Hepatitis C+3 more
Completed
2016-12past
1
Phase 3Elagolix
Uterine Fibroids+2 more
Completed
2018-02-14past
2
Phase 3adalimumab
Hidradenitis Suppurativa (HS)+4 more
Completed
2019-09-26past
6
Phase 3Upadacitinib
Rheumatoid Arthritis (RA)+2 more
Completed
2021-10-15past
3
Phase 3Temozolomide
Glioblastoma+1 more
Completed
2022-04-04past
1
Phase 3Placebo for Risankizumab
Psoriasis
Completed
2023-04-20past
1
Phase 3Cariprazine
Schizophrenia
Terminated
2024-09-20past
1
Phase 3Atogepant 60 mg
Episodic Migraine+1 more
Completed
2025-10-20past
1
Phase 2Unnamed
Skin Quality Deficit
Completed
2026-02-05past
1
Phase 3Lutikizumab
Hidradenitis Suppurativa
Active, not recruiting
2026-12
1
Phase 3Telisotuzumab Adizutecan
Metastatic Colorectal Cancer+2 more
Recruiting
2027-08
2
Phase 3Atogepant
Episodic Migraine+1 more
Recruiting
2028-03
2
Phase 2ABT-089
Attention-Deficit/Hyperactivity Disorder
Completed
2008-08past
1
Phase 2ABT-450
Hepatitis C+3 more
Completed
2011-06past
1
Phase 2ABT-384
Alzheimer's Disease
Completed
2011-07past
1
Phase 2ABT-126
Cognitive Deficits in Schizophrenia+1 more
Completed
2014-03past
2
Phase 2ABT-493
Chronic Hepatitis C+2 more
Completed
2015-06past
1
Phase 2ABT-494
Rheumatoid Arthritis
Completed
2015-07past
1
Phase 1ABT-263
Chronic Lymphoid Leukemia+6 more
Completed
2016-10past
2
Phase 2OBV/PTV/r
Chronic Hepatitis C Virus Infection
Completed
2017-07-14past
1
Phase 2Placebo
Progressive Supranuclear Palsy
Terminated
2019-11-20past
1
Phase 2ABBV-154
Polymyalgia Rheumatica
Terminated
2023-07-24past
1
Phase 2Elezanumab
Spinal Cord Injury (SCI)
Completed
2026-01-26past
1
Phase 2Telisotuzumab vedotin
Non-small Cell Lung Cancer
Active, not recruiting
2026-07past
1
Phase 2Livmoniplimab
Urothelial Carcinoma
Active, not recruiting
2027-03
1
Phase 2ABBV-142
Idiopathic Pulmonary Fibrosis
Recruiting
2029-09
1
Phase 1M200 (Volociximab), Carboplatin, Paclitaxel
Non-small Cell Lung Cancer
Completed
2010-05past
1
Phase 1Levodopa-Carbidopa
Parkinson Disease
Completed
2010-09past
1
Phase 1ABT-348
Acute Lymphoblastic Leukemia+4 more
Completed
2013-06past
1
Phase 1ABT-414
Glioblastoma Multiforme
Completed
2017-06-19past
1
Phase 1ABBV-838
Multiple Myeloma
Terminated
2017-12-06past
1
Phase 1Rovalpituzumab Tesirine
Small Cell Lung Cancer
Terminated
2019-05-31past
1
Phase 1ABBV-951
Parkinson's Disease (PD)
Completed
2019-06-08past
1
Phase 1ABBV-075
Cancer+7 more
Completed
2019-07-05past
1
Phase 1SDI-118
Cognitive Disorders
Completed
2019-07-29past
1
Phase 1ABBV-744
Acute Myeloid Leukemia (AML)
Terminated
2020-12-19past
1
Phase 1ABBV-467
Multiple Myeloma (MM)+1 more
Terminated
2021-04-16past
1
Phase 1ABBV-47D11
CoronaVirus Disease-2019 (COVID-19)
Completed
2021-08-24past
1
Phase 1Veliparib, capsule
Cancer - Ovarian
Withdrawn
2021-11-16past
1
Phase 1ABBV-903
Healthy Volunteers
Terminated
2023-10-30past
1
Phase 1ABBV-552
Healthy Volunteer
Completed
2024-04-19past
1
Phase 1ABBV-932
Generalized Anxiety Disorder (GAD)+1 more
Completed
2024-05-31past
1
Phase 1Icalcaprant
Healthy Volunteer
Completed
2025-01-17past
1
Phase 1Emraclidine
Healthy Volunteers
Active, not recruiting
2026-07past
1
Phase 1Ubrogepant
Healthy Volunteer
Not yet recruiting
2026-10
1
N/AUnnamed
Anesthesia, General
Completed
2013-07past
1
N/AUnnamed
Respiratory Syncytial Virus Infection
Completed
2013-08past
1
N/AUnnamed
HIV-1 Infection
Completed
2014-10past
1
N/AUnnamed
Rheumatoid Arthritis
Completed
2014-11past
1
N/AUnnamed
Crohn's Disease
Completed
2016-02past
1
N/AUnnamed
Rheumatoid Arthritis
Completed
2016-04past
1
N/ALopinavir / ritonavir
Human Immunodeficiency Virus Infection
Completed
2016-06past
1
N/AUnnamed
Rheumatoid Arthritis+2 more
Completed
2018-01-11past
1
N/AUnnamed
Chronic Hepatitis C Virus (HCV)
Completed
2018-04-25past
1
N/AUnnamed
Chronic Hepatitis C Virus
Completed
2019-02-28past
1
N/AUnnamed
Moderate to Severe Plaque Psoriasis
Completed
2019-04-19past
1
N/AUnnamed
Uveitis
Completed
2020-02-24past
1
N/AULTRESA
Fibrosing Colonopathy
Terminated
2020-04-08past
1
N/AUnnamed
Psoriasis
Completed
2020-08-25past
1
N/AUnnamed
Rheumatoid Arthritis (RA)
Completed
2024-07-30past
1
N/AUnnamed
Migraine
Completed
2024-08-05past
1
N/AUnnamed
Spasticity
Completed
2025-05-30past
1
N/AUnnamed
Cancer, Chronic Lymphocytic Leukemia (CLL)
Completed
2025-08-18past
1
N/AUnnamed
Bipolar I Disorder
Completed
2026-01-23past
1
N/AUnnamed
Atopic Dermatitis
Active, not recruiting
2026-10
1
N/AUnnamed
Advanced Parkinson's Disease
Recruiting
2027-01
1
N/AUnnamed
Ovarian Cancer
Not yet recruiting
2027-03
1
N/AUnnamed
Parkinson's Disease
Recruiting
2027-09
1
N/AUnnamed
Diabetic Retinopathy, DR
Enrolling
2028-05
1
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

No peer cohort defined for ABBV. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.